Notes
2013 US dollars
Reference
Dilokthornsakul P, et al. Forecasting US ivacaftor outcomes and cost in cystic fibrosis patients with the G551D mutation. European Respiratory Journal : 28 Apr 2016. Available from: URL: http://doi.org/10.1183/13993003.01444-2015
Rights and permissions
About this article
Cite this article
Ivacaftor improves QALYs at high cost but limited budget impact. PharmacoEcon Outcomes News 753, 24 (2016). https://doi.org/10.1007/s40274-016-3057-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3057-6